Compare FHN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHN | TGTX |
|---|---|---|
| Founded | 1864 | 1993 |
| Country | United States | United States |
| Employees | 7400 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 4.9B |
| IPO Year | N/A | 2008 |
| Metric | FHN | TGTX |
|---|---|---|
| Price | $22.50 | $32.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | $25.76 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 5.2M | 2.0M |
| Earning Date | 04-15-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $7.57 | $49.30 |
| Revenue Next Year | $4.19 | $24.55 |
| P/E Ratio | $13.42 | ★ $11.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.23 | $25.37 |
| 52 Week High | $26.56 | $46.48 |
| Indicator | FHN | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 61.57 |
| Support Level | $21.76 | $29.81 |
| Resistance Level | $23.08 | $32.96 |
| Average True Range (ATR) | 0.52 | 1.39 |
| MACD | 0.10 | 0.32 |
| Stochastic Oscillator | 62.10 | 92.82 |
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets. The Wholesale segment delivers industry-specific products and services, while the Corporate segment provides internal support functions like finance, risk, and audit.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.